Invasion of the bladder by transitional cell carcinoma: Its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2

Cancer

Volumn 82, Issue 4, 1998, Pages 715-723

  Vollmer, Robin T ^a   Humphrey, Peter A ^b   Swanson, Paul E ^b   Wick, Mark R ^b   Hudson, M'Liss A ^b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bcl 2; Bladder carcinoma; c erb B 2; Epidermal growth factor receptor; Invasion; MIB 1; p53

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BLADDER BIOPSY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; GROWTH RATE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LOGISTIC MODELS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0032519575     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980215)82:4<715::AID-CNCR15>3.0.CO;2-0     Document Type: Article

References (55)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 46:5-27.
2. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of urinary bladder specimens containing bladder neoplasms. Am J Clin Pathol 1996; 106:568-70.
3. Cutler SJ, Heney NM, Fiedell GH. Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In: Bonney W, Prout G Jr., editors. AUA Monographs. Baltimore: Williams and Wilkins, 1982:35.
4. Heney NM, Nocks BN, Daly JJ. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol 1991; 54: 152-7.
5. Kaubisch S, Lum BL, Reese J, Freiha F, Torti FM. Stage T1 bladder cancer: grade is primary determinant for risk of muscle invasion. J Urol 1991; 146:28-31.
6. Jewett HJ, Strong GH. Infiltrating carcinoma of the bladder: relationship of the depth of penetration of the bladder wall to the incidence of local extension and metastases. J Urol 1946; 55:366-70.
7. Weinstein RS, Miller AW, Pauli BU. Carcinoma in situ: comments on the pathobiology of a paradox. Urol Clin North Am 1980; 7:523-31.
8. Neal DE, Bennett MK, Hall RR, Marsh C, Abel PD, Sainsbury JRC, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985; 1:366-8.
9. Berger MS, Greenfield C, Gullick WJ, Haley J, Downward J, Neal DE, et al. Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer 1987; 56:533-7.
10. Neal DE, Sharpies L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65:1619-25.
11. Wright C, Mellon K, Neal DE, Johnston P, Corbett IP, Home CHW. Expression of c-erb B-2 protein product in bladder cancer. Br J Cancer 1990; 62:764-5.
12. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, et al. Amplification and over-expression of c-erb B-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 63:601-8.
13. Lipponen P, Eskelinen M, Syrjanen S, Tervahauta A, Syrjanen K. Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 1991; 20:238-42.
14. Moriyama M, Akiyama T, Yamamoto T, Kawamoto T, Kato T, Sato K, et al. Expression of c-erb B-2 gene product in urinary bladder cancer. J Urol 1991; 145:423-7.
15. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CHW, et al. Expression of mutant p53, c-erb B-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 1991; 63: 967-70.
16. Gardiner R, Smaratunga MLTH, Walsh MD, Seymour GJ, Lavin MF. An immunohistological demonstration of c-erb B-2 oncoprotein expression in primary urothelial bladder cancer. Urol Res 1992; 20:117-20.
17. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, et al. An immunohistologic evaluation of c-erb B-2 gene product in patients with urinary bladder carcinoma. Cancer 1992; 70:2493.
18. Swanson P, Frierson HF, Wick MR. c-erb B-2 (HER-2/neu) oncopeptide immunoreactivity in localized, high grade transitional cell carcinoma of the bladder. Mod Pathol 1992; 5: 531-6.
19. Chow N-H, Tzai T-S, Lin S-N, Chan S-H, Tang M-J. Reappraisal of the biological role of epidermal growth factor receptor in transitional cell carcinoma. Eur Urol 1993; 24: 140-3.
20. Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143:1289-397.
21. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:1259-64.
22. Furihata M, Inoue K, Ohtsuki Y, Hashimoto H, Terao N, Fujita Y. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 1993; 53:4823-7.
23. Lipponen P. Expression of c-erb B-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 1993; 29A:749-53.
24. Lipponen P. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Br J Cancer 1993; 53:365-70.
25. Moch H, Sauter G, Moore D, Mihatsch MJ, Gudat F, Waldman F. p53 and c-erb B-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A Pathol Anat 1993; 423:329-34.
26. Sarkis A, Dalbagni G, Cordon-Cardo C, Zhang Z-F, Sheinfeld J, Fair WR, et al. Nuclear overpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85:53-9.
27. Lee S-E, Chow N-H, Chi Y-C, Tzai T-S, Yang W-H, Lin S-N. Expression of c-erb B-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 1994; 14: 1317-24.
28. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erb B-2, p53) expression and long-term prognosis. Br J Cancer 1994; 69:1120-5.
29. Mazerolles C, Rishmann P, Chopin D, Popov Z, Malavaud B, Selves J, et al. Usefulness of MIB-1 monoclonal antibody in assessing the proliferation index in human bladder carcinoma: comparison with Ki-67 antibody. Histopathology 1994; 25:563-8.
30. Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: a multivariate survival analysis. Am J Clin Pathol 1994; 101:166-76.
31. Lacombe L, Dalbagni G, Zhang Z-F, Cordon-Cardo C, Fair WR, Herr HW, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. J Clin Oncol 1996; 14:2646-52.
32. Esrig D, Shi S-R, Bochner BH, Nichols PW, Chen S-C, Yang C, et al. Prognostic importance of p53 and RB alterations in transitional cell carcinoma of the bladder. Proc Am Urol Assoc 1995; 153(Suppl A):362A.
33. Ferrari G, Righi E, Castagnetti G, Dotti A, Ferrari P, De Gaetani C, et al. p53 and bcl-2 expression in superficial bladder cancer. Proc Am Urol Assoc 1995; 153(Suppl A):362A.
34. Click SH, Meyers F, DeVere White RW. Relationship of p53 and bcl-2 to prognosis in muscle invasive transitional cell carcinoma of the bladder. Proc Am Urol Assoc 1995; 153 (Suppl A):363A.
35. Lerner SP, Linn D, Chakraborty S, Truong L, Xu H-J, Wheeler TM, et al. Correlation of p53 and retinoblastoma protein expression with established pathologic prognostic features in radical cystectomy specimens. Proc Am Urol Assoc 1995; 153(Suppl A):363A.
36. Popov Z, Hoznek A, Colombel M, Bellot J, Abbou CC, Chopin D. p53 and proliferation are independent prognostic markers for bladder cancer. Proc Am Urol Assoc 1995; 153 (Suppl A):363A.
37. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995; 71:201-5.
38. Serth J, Kuczyk MA, Anton P, Hofner K, Jonas U. Mutational inactivation of the p53 tumor suppressor gene as a prognosticator in muscle invasive bladder cancer. Proc Am Urol Assoc 1995; 153(Suppl A):362A.
39. Bilim V, Tomita Y, Kawasaki T, Katagiri A. Prognostic value of bcl-2 and p53 expression in urinary tract transitional cell carcinoma. J Natl Cancer Inst 1996; 88:686-8.
40. Mellon JK, Lunec J, Wright C, Wilson Home CH, Kelly P, Neal DE. c-erb B-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996; 155:321-6.
41. Shiima H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, et al. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996; 78:1762-4.
42. Vollmer RT. Multivariate statistical analysis for pathologists. Part 1. The logistic model. Am J Clin Pathol 1996; 105:115-26.
43. S-Plus. StatSci Division, MathSoft, Inc., 1700 Westlake Ave N, Seattle, WA 98109.
44. Hunter T. Cooperation between oncogenes. Cell 1991; 64: 249-70.
45. Hudson MA, Humphrey PA, Swanson PE, Wick MR, Vollmer RT. Use of p53, MIB-1, EGER, c-erb B-2, bcl-2 as prognostic markers in bladder cancer patients. Proc Am Urol Assoc 1996; 155(Suppl A):615A.
46. Weinberg RA. The action of oncogenes in the cytoplasm and the nucleus. Science 1985; 230:770-6.
47. Chiou S-K, Rao L, White E. bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 1994; 14:2256-63.
48. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54:3131-5.
49. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cell lines. Cancer Res 1994; 54:2095-7.
50. Silvestrini R, Veroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86:499-504.
51. Marin MC, Hsu B, Meyn RE, Donehower LA, El-Naggar AK, Mcdonnell TJ. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 1994; 9:3107-12.
52. Vissher DW, Sarkar F, Tabaczka P, Crissman J. Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. Mod Pathol 1996; 9:642-6.
53. Hurlimann J, Larrinaga B, Vala DL. bcl-2 protein in invasive ductal breast carcinomas. Virchow Arch 1995; 426:163-168.
54. Joensuu H, Pylkkanen L, Toikkanen S. bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145:1191.
55. Bhaskar VSK, Figge J, Leibovich B, Hwang J, Rifkin M, Kaufman R, et al. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation. Mod Pathol 1996; 9:41-7.